Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2021; 13(8): 845-855
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.845
Recent update on comprehensive therapy for advanced hepatocellular carcinoma
Hui Wang, Wei Li
Hui Wang, Wei Li, Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China
Author contributions: Wang H initially collected and organized the literature and drafted the manuscript; Li W contributed to the conceptual design and carried out critical revision and finalization of the manuscript.
Supported by Nature Science Foundation of the Science and Technology Bureau of Jilin Province, No. 20190201227JC; and Innovation Capacity-building Fund of the Development and Reform Commission of Jilin Province, No. 2019C015.
Conflict-of-interest statement: The authors have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Li, MD, PhD, Professor, Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun 130033, Jilin Province, China. weili888@jlu.edu.cn
Received: February 18, 2021
Peer-review started: February 19, 2021
First decision: March 29, 2021
Revised: April 12, 2021
Accepted: June 23, 2021
Article in press: June 23, 2021
Published online: August 15, 2021
Processing time: 177 Days and 0.3 Hours
Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The curative effect can be achieved only for early stage HCC, and it is easy to recur and metastasize after surgery, with a 5-year recurrence rate as high as 70%. Recently, the systematic treatment of advanced HCC has made a breakthrough. Multidisciplinary comprehensive treatment including targeted therapy and immunotherapy has become an effective strategy and inevitable trend for the treatment of advanced HCC. Combined therapy has greatly improved the prognosis of HCC patients and opened up a new milestone in the treatment of this malignancy.